The store will not work correctly when cookies are disabled.
We use cookies for optimal website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.
Allow cookies Deny
UVI 3003; (E)-3-(4-hydroxy-3-(5,5,8,8-tetramethyl-3-(pentyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl)acrylic acid; CAS No.: 847239-17-2; UVI 3003. PROPERTIES: UVI 3003 is a crystalline compound with the molecular formula C29H25F3N4O4. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety precautions include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 540.52 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms and hydrogen bond donors/acceptors that enhance target binding. Its logP value around 2.9 indicates a balance between hydrophilic and lipophilic characteristics. APPLICATIONS: UVI 3003 serves as a selective inhibitor of the polo-like kinase 1 (PLK1), investigated for the treatment of various cancers including leukemia and solid tumors. In preclinical research, it is used to study PLK1's role in cell cycle regulation and to develop novel therapeutic approaches. The compound is employed in combination studies with other targeted therapies to enhance antitumor efficacy. Additionally, it functions as a research tool in cell biology to investigate PLK1-mediated cellular processes and in drug discovery to explore structure-activity relationships of PLK1 inhibitors. According to "Polo-Like Kinase 1 Inhibitors: A Comprehensive Review," UVI 3003 provides a promising approach to targeting PLK1 in cancer therapy.